Meproleaf

Meproleaf Brand names, Meproleaf Analogs

Meproleaf Brand Names Mixture

No information avaliable

Meproleaf Chemical_Formula

C₂₀H₂₃NS

Meproleaf RX_link

No information avaliable

Meproleaf fda sheet

Meproleaf msds (material safety sheet)

Meproleaf Synthesis Reference

No information avaliable

Meproleaf Molecular Weight

309.469 g/mol

Meproleaf Melting Point

< 25 ^oC

Meproleaf H₂O Solubility

Soluble as HCl salt

Meproleaf State

Liquid

Meproleaf LogP

5.7

Meproleaf Dosage Forms

Tablets (oral, 1 mg)

Meproleaf Indication

Used for the symptomatic treatment of parkinsonism.

Meproleaf Pharmacology

Metixene is a tertiary antimuscarinic with actions similar to those of atropine; it also has antihistaminic and direct antispasmodic properties. It is used for the symptomatic treatment of parkinsonism, including the alleviation of the extrapyramidal syndrome induced by other drugs such as phenothiazines, but, like other antimuscarinics, it is of no value against tardive dyskinesias. Metixene has been discontinued.

Meproleaf Absorption

Absorbed in the gastrointestinal tract following oral administration, however the extent of absorption is not known.

Meproleaf side effects and Toxicity

Signs of overdose include dilated and sluggish pupils, warm, dry skin, facial flushing, decreased secretions of the mouth, pharynx, nose, and bronchi, foul-smelling breath, elevated temperature, tachycardia, cardiac arrhythmias, decreased bowel sounds, urinary retention, delirium, disorientation, anxiety, hallucinations, illusions, confusion, incoherence, agitation, hyperactivity, ataxia, loss of memory, paranoia, combativeness, and seizures.

Meproleaf Patient Information

Meproleaf Organisms Affected

Humans and other mammals